** U.S.-listed shares of Australia's Immuron Ltd IMRN.O
surge 72.7% to $3.23 premarket
** Co IMC.AX says FDA removes clinical hold, allowing the
U.S. Naval Medical Research Center to evaluate efficacy of
diarrhoea drug, Travelan
** Travelan, co-developed with Immuron, is an oral
immunotherapeutic drug to treat gut-mediated diseases caused by
various types of bacteria
** Drug's safety and efficacy will be tested in two trials,
with one focusing on the drug's ability against ETEC infections
and the focusing on moderate to severe campylobacteriosis
** As of last close, stock down ~15% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))